Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026

American Fusion Inc. (OTC: AMFN) Receives Texas DSHS Certificate for All 12 Registered Texatron™ Fusion Engine™ Models; Testing Expected the Week of July 27, 2026

View original at globenewswire.com
American Fusion Inc. (OTC: AMFN) Receives Texas DSHS Certificate for All 12 Registered Texatron™ Fusion Engine™ Models; Testing Expected the Week of July 27, 2026 SOUTHLAKE, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- American Fusion Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The certificate does not certify commercial performance but provides authorization to conduct the covered research program; the next objective is generating credible, reproducible and properly documented technical data.

    60% confidence

  • The DSHS certificate covering all 12 registered Texatron™ models represents one of the most significant operational milestones in the Company's development and moves it closer to obtaining technical data required for future commercialization.

    60% confidence

  • This milestone represents another major step in American Fusion's development, bringing together scientific innovation, regulatory discipline, experienced personnel and a clear testing program.

    60% confidence

  • Excitement about beginning planned Texatron™ testing at Texas Tech, applying advanced scientific instrumentation and disciplined testing procedures to evaluate an innovative compact-fusion platform.

    60% confidence

  • Receiving the certificate for all 12 Texatron™ model classes is an extraordinary achievement enabling a new phase of disciplined experimental evaluation, including re-testing the 500-kilowatt system and beginning work on the 5-megawatt Texatron™.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com